glp-1 gip therapy alternatives 2025 Natural Alternatives: Supporting Metabolic Health Adjunctive Treatment with GLP-1 and
Description
Eli Lilly is also developing a drug called retatrutide, that targets three receptors (glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors)
M., & Emond, S
GuzmanCBZhangXMLiuRRegevAShankarSGarhyanPet al
As Wegovy, it received FDA approval specifically for the treatment of obesity in 2021
Clinical Trials.gov
